.

Share price of this healthcare stock moved up by nearly 2.58% on BSE to Rs. 648.75 in the trading session of March 28th, compared to its previous close of Rs. 632.4, after a large bulk deal via open market transactions. 

With a market capitalisation of Rs. 6,529.6 crores, at 01:10 p.m. the shares of Vijaya Diagnostic Centre Limited were trading in the green at Rs. 635.95, up by 0.36 percent. 

In the last one year, the company has delivered positive returns of about 57.3 percent and nearly 28.07 percent in the last six months. However, so far in 2024, it has given negative returns of around 5.8 percent. 

According to the bulk deal data available on the NSE, Kotak Mahindra Mutual Fund bought 8.1 lakh equity shares in Vijaya Diagnostic Centre Limited on Wednesday. 

The total transaction value was about Rs. 51.03 crore, and the shares were purchased at an average price of Rs. 630. 

In terms of financials, the company’s revenue from operations grew by nearly 17.7 percent YoY from Rs. 113 crore in Q3 FY22-23 to Rs. 133 crore in Q3 FY23-24. 

Further, the net profit also increased by 62.5 percent YoY, from Rs. 16 crore in Q3 FY22-23 to Rs. 26 crore in Q3 FY23-24. 

As of December 2023, FIIs hold 19.95 percent of the shares, whereas DIIs hold 19.82 percent of the shares in the company, aggregating to 39.77 percent of the institutional holdings. 

Vijaya Diagnostic Centre Limited is one of India’s Leading Diagnostic Centre Networks and offers a one-stop solution for pathology and radiology testing services through our extensive operational network. 

Written by Shivani Singh 

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.